(Hypertension. 2001;38:404.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Differential Subcellular Actions of ACE Inhibitors and AT1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
Correspondence to Masafumi Kitakaze, MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871 Osaka, Japan. E-mail kitakaze{at}medone.med.osaka-u.ac.jp
Abstract—— Chronic inhibition of NO synthesis induces cardiac hypertrophy independent of systemic blood pressure (SBP) by increasing protein synthesis in vivo. We examined whether ACE inhibitors (ACEIs) enalapril and temocapril and angiotensin II type-I receptor antagonists (angiotensin receptor blockers [ARBs]) losartan and CS-866 can block cardiac hypertrophy and whether changes in activation of 70-kDa S6 kinase (p70S6K) or extracellular signal–regulated protein kinase (ERK) are involved. The following 13 groups were studied: untreated Wistar-Kyoto rats and rats treated with NO synthase inhibitor N
-nitro-L-arginine methyl ester (L-NAME), D-NAME (the inactive isomer of L-NAME), L-NAME plus hydralazine, L-NAME plus enalapril (3 mg · kg-1 · d-1) or temocapril (1 or 10 mg · kg-1 · d-1), L-NAME plus losartan (10 mg · kg-1 · d-1) or CS-866 (1 or 10 mg · kg-1 · d-1), L-NAME plus temocapril-CS866 in combination (1 or 10 mg · kg-1 · d-1), and L-NAME plus rapamycin (0.5 mg · kg-1 · d-1). After 8 weeks of each experiment, ratios of coronary wall to lumen (wall/lumen) and left ventricular weight to body weight (LVW/BW) were quantified. L-NAME increased SBP, wall/lumen, and LVW/BW compared with that of control. ACEIs, ARBs, and hydralazine equally canceled the increase in SBP induced by L-NAME. However, ACEIs and ARBs equally (but not hydralazine) attenuated increase in wall/lumen and LVW/BW induced by L-NAME. The L-NAME group showed both p70S6K and ERK activation in myocardium (2.2-fold and 1.8-fold versus control, respectively). ACEIs inactivated p70S6K and ARBs inactivated ERK in myocardium, but hydralazine did not change activation of either kinase. Thus, ACEIs and ARBs modulate different intracellular signaling pathways, inhibiting p70S6K or ERK, respectively, to elicit equal reduction of cardiac hypertrophy induced by chronic inhibition of NO synthesis in vivo.
Key Words: remodeling • angiotensin-converting enzyme inhibitor • receptors, angiotensin • kinase
This article has been cited by other articles:
 |
|
 |
|
  J. Yatabe, H. Sanada, M. S. Yatabe, S. Hashimoto, M. Yoneda, R. A. Felder, P. A. Jose, and T. Watanabe Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1052 - F1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1281 - H1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bell, Y.-Y. Zhao, E. J. Kelso, E. M. McHenry, L. M. Rush, V. M. Lamont, D. P. Nicholls, and B. J. McDermott Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H904 - H914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Hu, L. A. Benvenuti, E. A. Liberti, M. S. Carneiro-Ramos, and M. L. M. Barreto-Chaves Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1473 - R1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, K. Node, T. Minamino, S. Takashima, A. Ogai, H. Asanuma, H. Ogita, Y. Liao, M. Asakura, J. Kim, et al. Long-Acting Ca2+ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in Rats Hypertension, April 1, 2003; 41(4): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakamura, M. Yoshiyama, T. Omura, K. Yoshida, Y. Izumi, K. Takeuchi, S. Kim, H. Iwao, and J. Yoshikawa Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction Cardiovasc Res, January 1, 2003; 57(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Suda, M. Tsutsui, T. Morishita, A. Tanimoto, M. Horiuchi, H. Tasaki, P. L. Huang, Y. Sasaguri, N. Yanagihara, and Y. Nakashima Long-Term Treatment With N{omega}-Nitro-L-Arginine Methyl Ester Causes Arteriosclerotic Coronary Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice Circulation, September 24, 2002; 106(13): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, K. Node, H. Asanuma, H. Ogita, S. Takashima, T. Minamino, M. Asakura, Y. Liao, A. Ogai, J. Kim, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: Role of 70-kDa S6 kinase and extracellular signal-regulated kinase J. Am. Coll. Cardiol., September 4, 2002; 40(5): 991 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Lang Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality? Heart, April 1, 2002; 87(4): 316 - 317. [Full Text] [PDF]
|
|